Loading…
RFL
Rafael Holdings, Inc.
NYSE· Real Estate· Real Estate Services· CUSIP 75062E106
$2.000.00%Price as of Sep 22, 22:39 UTC · updated once a day, after the close
Key metrics
- Market cap
- $104M
- P/E
- —
- Forward P/E
- —
- P/B
- 1.4x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.72
- ROE
- -37.59%
- Profit margin
- 0.00%
- Revenue growth
- -50.60%
- Beta
- 0.40
- 52-week high
- $3.96
- 52-week low
- $1.12
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -74.0% over 5Y.
today you would have $64.01▼ -93.6%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 3 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Year-end price | $1.63 | $1.80 | $1.84 | |
| P/S | 111.7x | 63.8x | 159.3x | 111.7x |
| P/B | 0.5x | 0.5x | 0.4x | 0.5x |
| EPS | -$1.43 | -$0.08 | -$6.22 | |
| Profit margin | -5401.88% | -5401.88% | -672.40% | -30404.39% |
| ROE | -41.87% |
Others in the same sector
Companies of similar size in Real Estate, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| SRGSeritage Growth Properties | $1.85 | — | 0.4x | — | -16.73% | $104.2M |
| SDHCSmith Douglas Homes Corp. | $12.34 | 17.1x | 1.3x | — | 9.22% | $103.56M |
| CHMICherry Hill Mortgage Investment Corp | $2.76 | 13.1x | 0.8x | 14.49% | 7.20% | $103.44M |
| SUNSSunrise Realty Trust, Inc. |
About the company
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Type C1 ("NPC1"), a rare, fatal and progressive genetic disorder; and CPI-613 (devimistat), a stable analog of normally transient, acylated catalytic intermediates of lipoate, which is in phase II of clinical trial. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
- 21
- Newark, United States
Company description provided by Yahoo Finance.